The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
CA 19–9 and CE A are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis
Abstract
Aims/Background: Diagnosis of early cholangiocarcinoma (CC) in patients with primary sclerosing cholangitis with available radiological methods is very difficult. This type of tumor is the second most common cause of mortality after liver failure in these patients. The recognition of CC is important for the selection of patients for, and the results of, liver transplantation (Ltx). In this study our aim was to investigate the value of measuring cancer markers (CA 19–9 and CEA) in patients with PSC for early diagnosis of CC. Methods: 72 PSC patients who were followed at our institution for a long period were included in the study; 9 with CC and 63 without CC. Furthermore, nine patients with CC but without concomitant PSC were included, as well as 24 patients with various cholestatic liver diseases. Serum levels of CA 19–9 and CEA were measured, in 39 PSC patients without CC, on multiple occasions. Moreover, bile was collected during a diagnostic ERCP from 20 patients for measurements of CA 19–9 and CEA. Results: In those PSC patients without CC during the follow‐up and with more than one year of follow‐up, 15 patients had increased values of CA 19–9 (>37 ng/ml) on some of the occasions. Four of them demonstrated large fluctuations (more than 100 ng/ml difference at different occasions) in serum levels of Ca 19–9. A significant correlation between high CA 19–9 values and serum alkaline phosphatase levels was observed in these patients. The sensitivity of CA 19–9 in detecting CC in PSC patients was only 63%. The sensitivity of CEA and the combination of CA 19–9 and CEA (marker product; King's College formula) were still lower (33%) although the specificity was relatively high (85%). Bile levels of the tumor markers did not demonstrate any clinically useful differences between the different patient groups. Conclusions: Tumor markers as a diagnostic tool in diagnosing CC in patients with PSC are unfortunately not as valuable as previously reported. The serum levels of CA 19–9 can rise temporarily in association with a “biochemical relapse” of PSC (increased values of serum alkaline phosphatase). The marker product of CA 19–9 and CEA has a low sensitivity but a relatively high specificity for the detection of CC in PSC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural history and prognostic variables in primary sclerosing cholangitis
Farrant, J. M., Hayllar, K. M., Wilkinson, M. L., Karani, J., Portmann, B. C., Westaby, D., & Williams, R. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90673-9 · Cited by 468
Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis
Ramage, J. K., Donaghy, A., Farrant, J. M., Iorns, R., & Williams, R. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90462-x · Cited by 279
Cited by
Incidence and Risk Factors for Cholangiocarcinoma in Primary Sclerosing Cholangitis
Burak, K., Angulo, P., Pasha, T. M., Egan, K., Petz, J., & Lindor, K. D. (2004) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2004.04067.x · Cited by 557
A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis
Mitchell, S. A., Bansi, D. S., Hunt, N., Bergmann, K. V., Fleming, K. A., & Chapman, R. W. (2001) · Gastroenterology · doi:10.1053/gast.2001.27965 · Cited by 351
Levy, C., Lymp, J., Angulo, P., Gores, G. J., Larusso, N., & Lindor, K. D. (2005) · Digestive Diseases and Sciences · doi:10.1007/s10620-005-2927-8 · Cited by 339
“However, other investigators have questioned the utility of this tumor marker in predicting development of cholangiocarcinoma or other pancreaticobiliary tumors due to a high falsepositivity rate (11, 18 , 19).”
BackgroundDiagnosis and Treatment of Cholangiocarcinoma
Anderson, C. D., Wright Pinson, C., Berlin, J., & Chari, R. S. (2004) · The Oncologist · doi:10.1634/theoncologist.9-1-43 · Cited by 332
Rerknimitr, R., Angsuwatcharakon, P., Ratanachu‐ek, T., Khor, C. J. L., Ponnudurai, R., Moon, J. H., Seo, D. W., Pantongrag‐Brown, L., Sangchan, A., Pisespongsa, P., et al. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12128 · Cited by 254
Metadata
- Authors
- Björnsson, E., Kilander, A., & Olsson, R.
- Venue
- Liver
- Publisher
- Wiley
- Published
- 1999-12
- Volume
- 19
- Issue
- 6
- Pages
- 501-508
- ISSN
- 0106-9543 (ISSN-L)
- 1600-0676
- OpenAlex
- W1974973209
- Cited by
- 146
- References
- 2
- FWCI
- 3.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CA 19–9 and CE A are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. https://app.cochat.ai/papers/10.1111/j.1478-3231.1999.tb00083.x
- The paper
- Björnsson, E., Kilander, A., & Olsson, R. (1999). CA 19–9 and CE A are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis. Liver. https://doi.org/10.1111/j.1478-3231.1999.tb00083.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.